Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Allergan is racking up another new deal in the wake of its broken merger with Pfizer... This new addition to the pipeline also fits neatly into Saunders'…
Board-certified dermatologist Jeffrey Dover called a topical fat-reduction option 'an important step forward'; Phase 2 placebo-controlled trial demonstrated…
The deal makes sense for Botox-maker Allergan, which already has a strong presence in the market for medical and facial aesthetics. An estimated 40 million…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Allergan acquired Topokine Therapeutics, a clinical-stage company developing topical medicines for fat reduction. Allergan paid $85M upfront plus undisclosed success-based development and sales milestones for XAF5, a first-in-class topical agent in late-stage development for steatoblepharon (under-eye bags).
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Allergan plc / Topokine Therapeutics, Inc. (this deal) | 2016 | $85M | 17 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Allergan plc / SkinMedica, Inc. | 2012 | $375M | 55 |
| Allergan plc / Inamed Corporation | 2005 | $3.2B | 50 |
| Allergan plc / Oculeve, Inc. | 2015 | $250M | 33 |
| Allergan plc / Zeltiq Aesthetics, Inc. | 2017 | $2.5B | 32 |
| Allergan plc / Kythera Biopharmaceuticals, Inc. | 2015 | $2.1B | 23 |
← Browse all deals · How we score deals
More: 2016 deals · Allergan plc deals · Dermatology deals